Vertex advances pipeline with NDA submission for cystic fibrosis
07 May 2024
NDAOrphan DrugFast TrackAcquisition
Vertex Pharmaceuticals has kicked off 2024 by staying busy, submitting a new drug application to the FDA for its cystic fibrosis (CF) therapy, vanzacaftor triple combination, and a corresponding marketing authorization application to the European Medicines Agency.
The vanzacaftor/tezacaftor/deutivacaftor combination has received Fast Track and Orphan Drug designations from the FDA for CF treatment. Vertex submitted its NDA using a priority review voucher.
In CF, mutations reduce the amount and function of the CFTR protein on cell surfaces. The medications vanzacaftor and tezacaftor help increase CFTR protein levels by improving its processing and transport to the cell surface. Deutivacaftor, meanwhile, enhances the protein's function, boosting salt and water flow across cell membranes.
In addition to its cystic fibrosis advancements, Vertex also recently reported a strong financial performance for the first quarter with product revenues rising to $2.69 billion, a 13% increase from the first quarter of 2023. This growth is attributed to the continued success of blockbuster Trikafta in both U.S. and international markets, especially following its approval for younger cystic fibrosis patients.
The drugmaker has also initiated a rolling NDA submission for suzetrigine (VX-548) for the treatment of moderate-to-severe acute pain, expected to be completed within the quarter. Suzetrigine represents a new class of pain management solutions that could potentially offer an alternative to traditional opioids.
Recently, Vertex also announced the acquisition of Alpine Immune Sciences. The deal includes povetacicept, a phase 3-ready asset for IgA nephropathy (IgAN), poised to become a leading treatment option for this chronic kidney disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.